GLP-1 Calorie Calculator: Ozempic, Wegovy & Tirzepatide Targets

GLP-1 medications blunt appetite drastically, causing severe hypocaloric states. Without adequate protein (1.2 to 1.5g/lb lean mass), up to 40% of lost weight can come from vital muscle tissue.

Women should generally not consume fewer than 1,200 calories per day, and men not fewer than 1,500 calories per day, to prevent severe nutrient deficiencies and gallstone formation.

GLP-1 receptor agonists (such as semaglutide in Ozempic/Wegovy and tirzepatide in Mounjaro/Zepbound) drastically delay gastric emptying and suppress hypothalamic hunger signals. Without a structured caloric floor, patients frequently slide into severe sub-clinical malnutrition (<1,000 kcal/day), triggering rapid muscle catabolism, hair loss (telogen effluvium), and metabolic down-regulation.

To prevent sarcopenic obesity (the loss of skeletal muscle mass while retaining visceral body fat) and protect organ metabolic rate, clinical endocrinology consensus establishes a minimum safety floor of 1,200 daily calories for women and 1,500 calories for men, unless directly supervised under an inpatient medical fasting protocol.

Clinical trial DEXA body composition analyses reveal that up to 35% to 40% of total weight lost on semaglutide can come from lean body mass. Elevating daily protein intake to 1.2–1.5 grams per pound of Lean Body Mass (LBM)—paired with progressive resistance training—is the proven clinical defense against myofibrillar muscle degradation.

In individuals with Class II or III obesity, standard weight-based TDEE formulas severely overestimate resting caloric expenditure because adipose fat is metabolically inert compared to muscle. The validated Boer formula isolates true Lean Body Mass (bone, water, organ, and muscle tissue), providing an accurate baseline for protein dosing and caloric floors.

GLP-1 receptor agonists enhance glucose-dependent insulin secretion and suppress postprandial glucagon release. By pairing our macro calculator with continuous glucose monitoring (CGM) data, patients can identify complex carbohydrate thresholds that maintain flat 24-hour glycemic curves without triggering gastrointestinal nausea.

Yes. DEXA scan body composition analyses from major semaglutide clinical trials (SURMOUNT, STEP) consistently show that 25% to 40% of total weight lost on GLP-1 medications comes from lean mass—including skeletal muscle—rather than fat. This is significantly higher than weight loss achieved through diet alone. The two proven countermeasures are consuming high protein (at least 1.2g per pound of lean body mass daily) and performing at least 2 to 3 progressive resistance training sessions per week throughout the entire GLP-1 treatment period.

Yes. Creatine monohydrate has no known drug interactions with semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound). Creatine is one of the most clinically researched supplements for preserving lean muscle mass during weight loss. A daily maintenance dose of 3 to 5 grams of creatine monohydrate, combined with adequate protein and resistance training, is an evidence-backed strategy specifically recommended for GLP-1 users to offset the elevated muscle loss risk. Use our our interactive tool.

Nausea is the most common GLP-1 side effect and is worsened by greasy, high-fat, spicy, or large-volume meals. To minimize symptoms while meeting your elevated protein needs: prioritize easily digestible, high-protein foods (Greek yogurt, eggs, cottage cheese, lean poultry, protein shakes); eat small, frequent meals of 200 to 300 calories; avoid liquid calories, highly processed foods, and alcohol; and stay well hydrated with electrolytes. Use our our interactive tool.

Ozempic (semaglutide 0.25 to 1.0 mg weekly, dosed for type 2 diabetes) suppresses appetite moderately, so a structured deficit is still required. Build your target as a TDEE-based deficit of 300 to 500 calories below maintenance, but never below the clinical safety floor of 1,200 kcal/day for women and 1,500 kcal/day for men. Keep protein elevated at 1.2 to 1.5 g per pound of lean body mass to protect muscle during weight loss.

Wegovy is high-dose semaglutide (up to 2.4 mg weekly) for weight management. STEP trials show average weight loss of about 15% at 68 weeks, but DEXA analyses show 25% to 40% of lost weight can be lean mass. Your calorie target should sit at or above the 1,200 / 1,500 kcal safety floor with protein at 1.2 to 1.5 g per pound of lean body mass, paired with resistance training to defend muscle.

Mounjaro (tirzepatide, dual GIP/GLP-1 agonist for type 2 diabetes) produces stronger appetite suppression than semaglutide, with SURMOUNT trials showing 15% to 21% average weight loss at the highest dose. Because under-eating is a real risk, treat the 1,200 / 1,500 kcal floor as a target rather than a minimum, and schedule protein-rich meals before appetite is suppressed.

Zepbound is tirzepatide dosed for weight management and has the strongest appetite-suppression profile of the GLP-1 class. Users frequently drift below 1,000 kcal/day unintentionally, accelerating muscle loss and hair shedding. Structure your plan around the 1,200 / 1,500 kcal floor plus an elevated protein target (1.2 to 1.5 g per pound of lean body mass), and consider creatine to further defend lean mass during treatment.

Because tirzepatide produces larger total weight losses, the absolute amount of lean mass lost can be greater even when the percentage is comparable. In clinical body-composition analyses, roughly one-quarter to one-third of total weight lost on GLP-1 therapy can come from lean mass, making protein intake and resistance training essential on every medication in this class.